Neurological Disease

3-p-FBT (hydrochloride) (3b-FBT (hydrochloride); Fluorotropacocaine (hydrochloride)) is an analytical reference standard that is structurally categorized as a tropane alkaloid.

Tmem175 modulator 2 (example 180) is a TMEM175 modulator.Tmem175 modulator 2 can be used for the research of neurodegenerative disorders.

Methiothepin (Metitepine; Ro 8-6837) is a potent and non-selective 5-HT₂ receptor antagonist, with pK_ds of 7.10 (5-HT_1A), 7.28 (5HT_1B), 7.56 (5HT_1C), 6.99 (5HT_1D), 7.0 (5-HT_5A), 7.8 (5-HT_5B), 8.74 (5-HT₆), and 8.99 (5-HT₇), and pK_is of 8.50 (5HT_2A), 8.68 (5HT_2B), and 8.35 (5HT_2C).

BIIB076 is a human monoclonal antibody (mAb) targeting PHF-tau. BIIB076 can be used for passive immunity research in Alzheimer's disease (AD).

Antazoline (phosphate) (Standard) is the analytical standard of Antazoline (phosphate). This product is intended for research and analytical applications. Antazoline phosphate is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline phosphate can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline phosphate can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline phosphate can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC₅₀ of 2.910 μmol/L in HepAD38 cells. Antazoline phosphate also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC₅₀ = 2.349 μmol/L). Antazoline phosphate has anti-arrhythmic effect in acute myocardial infarctions. Antazoline phosphate can be studied in research for cardiovascular diseases, and HBV.

SDUY816 is an oral active dual APN/NEP inhibitor, with IC₅₀ values of 0.68 μM for APN and 6.9 μM for NEP. SDUY816 exhibits analgesic effects and demonstrates good safety and pharmacokinetic profiles, with an oral bioavailability of 27% and a half-life of 4.02 hours in rats (oral administration, 10 mg/kg). SDUY816 has potential applications in the research of neuropathic pain disorders.

MRK 003 is an orally active γ-secretase inhibitor. MRK 003 targets the Notch signaling pathway by blocking the proteolytic cleavage of Notch receptors. MRK 003 inhibits tumor cell proliferation, induces apoptosis, downregulates anti-apoptotic proteins, upregulates phosphorylated Akt, suppresses angiogenesis, and overcomes microenvironment-mediated proliferative protection. MRK 003 can be used in research related to lung cancer, multiple myeloma, non-Hodgkin's lymphoma, pancreatic ductal adenocarcinoma, glioblastoma, and breast cancer.

DTI 0009 is a selective adenosine A1 receptor agonist used to reduce heart rate in patients with atrial fibrillation and to treat arrhythmias.

CGP-49823 is an orally active and highly selective antagonist of the neurokinin 1 receptor (NK1 receptor). CGP-49823‘s potency is significantly higher in isolated spinal cords of hamsters than in those of rats. CGP 49823 exhibits a significant anti-anxiety effect in social interaction experiments of rats, and its tolerance develops slowly, without causing anxiety-like withdrawal reactions after discontinuation. CGP-49823 can be used in anxiety and depression research.

mGluR2 agonist 1 (Compound 5b) is a potent and selective metabotropic glutamate 2 receptor (mGluR) agonist with an EC₅₀ of 82 nM. mGluR2 agonist 1 can be used for the research of central nervous system (CNS) diseases.

DOR agonist 2 (Compound 3) is a Delta Opioid Receptor agonist. DOR agonist 2 can inhibit the expression of TNF-α, prevent NF-κB transport to the nucleus, and activate the G protein-mediated ERK1/2 pathway. DOR agonist 2 can be used in the study of neurodegenerative diseases.

Kv3.1 activator-1 is a Kv3.1 voltage-gated potassium channel activator. Kv3.1 activator-1 exhibits distinct activating efficacy in both thallium flux assays and automated patch-clamp electrophysiological assays .

Sichuan pepper extract (Zanthoxylum bungeanum maxim. extract) is an extract of Sichuan pepper (Zanthoxylum bungeanum Maxim.) that has neuroprotective effects.

KCa2 channel modulator 2 (compound 2q) is a potent subtype-selective positive modulator of K_Ca2 channel. KCa2 channel modulator 2 exhibits similar potency on the rat K_Ca2.2a and human K_Ca2.3 channel subtypes, with EC₅₀s of 0.64 μM and 0.60 μM, respectively

CGS-9896 is an orally active benzodiazepine receptor agonist that targets the benzodiazepine receptor allosterically coupled to the GABA_A receptor and chloride ion carrier channel. The K_i value of CGS-9896 for benzodiazepine receptors in rats is 0.83 nM. CGS-9896 inhibits pentylenetetrazol-induced convulsions in mice and exerts an anticonvulsant effect.

RIPK1-IN-34 is a selective, brain-penetrant RIPK1 inhibitor (IC₅₀ = 126.70 nM) with almost no inhibitory effect on RIPK3 (IC₅₀ ＞ 10, 000 nM). RIPK1-IN-34 offers substantial neuroprotection by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) within the necroptosis pathway. RIPK1-IN-34 shows the neuroprotective effect in a rat middle cerebral artery occlusion (MCAO) model. RIPK1-IN-34 can be used for the study of anti-acute ischemic stroke (AIS).

RP-001 is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC₅₀ of 9 pM. RP-00 induces internalization and polyubiquitination of S1P1. RP-001 has little activity on S1P2-S1P4 and only moderate affinity for S1P5.

Cy3 labled Tofersen sodium is a Cy3 labled Tofersen sodium.

Mofegiline (MDL-72974) is an orally active and blood-brain barrier-penetrant MAO-B/SSAO selective inhibitor, with an IC₅₀ of 3.6 nM for MAO-B and 10 nM for SSAO. Mofegiline is a cationic amphiphilic compound that can induce indirect sympathomimetic effects, lysosomal accumulation, hERG channel interactions, phospholipidosis, and cell death. Mofegiline protects mice from MPTP-induced depletion of striatal dopamine, DOPAC, and HVA. Mofegiline can be used in research related to Parkinson's disease.

AAK1-IN-9 (Compound 3) is an AAK1 (adaptor associated kinase 1) inhibitor with an IC₅₀ of 10.92 nM. AAK1-IN-9 can be used in the study of neurodegenerative diseases.